Reactivity of the 1,3-β-D-glucan assay during bacteraemia: Limited evidence from a prospective study

Mycoses

Volumn 56, Issue 2, 2013, Pages 101-104

  Racil, Zdenek ^a,b   Kocmanova, Iva ^a   Toskova, Martina ^a   Winterova, Jana ^a   Lengerova, Martina ^a   Timilsina, Shira ^a   Mayer, Jiri ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

1,3 D glucan; Bacteraemia; Haematological malignancy

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA 1,3 GLUCAN; CEFEPIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; GENTAMICIN; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIUM CULTURE; BLOOD SAMPLING; BLOODSTREAM INFECTION; CLINICAL ARTICLE; FALSE POSITIVE RESULT; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIA; BETA-GLUCANS; HUMANS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

BACTERIA (MICROORGANISMS);

EID: 84874336479     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2012.02210.x     Document Type: Article

References (25)

1. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-75.
2. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
3. von Eiff M, Roos N, Schulten R et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995; 62: 341-7.
4. Garey KW, Rege M, Pai MP et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43: 25-31.
5. Kedzierska A, Kochan P, Pietrzyk A et al. Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and (1-->3)-beta-D-glucan antigens. Eur J Clin Microbiol Infect Dis 2007; 26: 755-66.
6. Obayashi T, Negishi K, Suzuki T et al. Reappraisal of the serum (1-->3)-beta-D-glucan assay for the diagnosis of invasive fungal infections - a study based on autopsy cases from 6years. Clin Infect Dis 2008; 46: 1864-70.
7. Odabasi Z, Mattiuzzi G, Estey E et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199-205.
8. Pazos C, Ponton J, Del Palacio A. Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43: 299-305.
9. Ellis M, Al-Ramadi B, Finkelman M et al. Assessment of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol 2008; 57: 287-95.
10. Racil Z, Kocmanova I, Lengerova M et al. Difficulties in using 1, 3-{beta}-D-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies--high frequency of false-positive results and their analysis. J Med Microbiol 2010; 59: 1016-22.
11. Kanda H, Kubo K, Hamasaki K et al. Influence of various hemodialysis membranes on the plasma (1-->3)-beta-D-glucan level. Kidney Int 2001; 60: 319-23.
12. Kanamori H, Kanemitsu K, Miyasaka T et al. Measurement of (1-3)-beta-D-glucan derived from different gauze types. Tohoku J Exp Med 2009; 217: 117-21.
13. Kimura Y, Nakao A, Tamura H et al. Clinical and experimental studies of the limulus test after digestive surgery. Surg Today 1995; 25: 790-4.
14. Usami M, Ohata A, Horiuchi T et al. Positive (1-->3)-beta-D-glucan in blood components and release of (1-->3)-beta-D-glucan from depth-type membrane filters for blood processing. Transfusion 2002; 42: 1189-95.
15. Mennink-Kersten MA, Warris A, Verweij PE. 1, 3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med 2006; 354: 2834-5.
16. Kedzierska A. (1 --> 3)-beta-D-glucan - a new marker for the early serodiagnosis of deep-seated fungal infections in humans. Pol J Microbiol 2007; 56: 3-9.
17. Mennink-Kersten MA, Verweij PE. Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am 2006; 20: 711-27.
18. Lequette Y, Odberg-Ferragut C, Bohin JP et al. Identification of mdoD, an mdoG paralog which encodes a twin-arginine-dependent periplasmic protein that controls osmoregulated periplasmic glucan backbone structures. J Bacteriol 2004; 186: 3695-702.
19. Mennink-Kersten MA, Ruegebrink D, Verweij PE. Reactivity of Bacteria with the 1, 3-beta-Glucan Assay (M-568). Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: American Society for Microbiology, 2007.
20. Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1, 3-beta-D-glucan assay reactivity. Clin Infect Dis 2008; 46: 1930-1.
21. Albert O, Toubas D, Strady C et al. Reactivity of (1-->3)-beta-d-glucan assay in bacterial bloodstream infections. Eur J Clin Microbiol Infect Dis 2011; 30: 1453-60.
22. Pickering JW, Sant HW, Bowles CA et al. Evaluation of a (1->3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43: 5957-62.
23. Metan G, Koc AN, Agkus C et al. Can bacteraemia lead to false positive results in 1, 3-beta-d-glucan test? Analysis of 83 bacteraemia episodes in high-risk patients for invasive fungal infections. Rev Iberoam Micol 2011. Epub ahead of print.
24. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
25. Digby J, Kalbfleisch J, Glenn A et al. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 2003; 10: 882-5.